(NewsDirect)
Immunic Inc (NASDAQ:IMUX) president andCEO Dr Daniel Vitt joined Thomas Warner from Proactive ahead of WorldBrain Day to provide an update on the biotechnology company'snovel multiple sclerosis (MS) treatment.
Dr Vitt gives an overview of the treatment that Immunic iscurrently working on, and emphasisedsthe significance of addressingthe high unmet medical need for MS patients worldwide. Immunic'sfocus is on developing a new therapeutic option, using vidofludimuscalcium, to treat both relapsing and progressive forms of MS.
He says that the drug is the first knownmodulator of the "so-called Nurr1 target", making it apotential neuroprotective treatment. Immunic is conducting a phase twoclinical study into its treatment for progressive MS, with biomarkerdata expected in the second half of the year. Dr Vitt saysregistration studies for relapsing MS are progressing well, with aninterim analysis anticipated next year.
He adds that the MS market holds significant potential due todemand for treatments that strike a good balance between being botheffective and tolerable, and says that "if we could confirm in thephase three study that the drug really prevents disability worseningthat would be a big step for patients."
ContactDetails
Proactive United States
+1347-449-0879
Copyright (c) 2023 TheNewswire - All rights reserved.